
These guidelines refer to the use of corticosteroids (deflazacort, prednisolone and vamorolone) in people with Duchenne muscular dystrophy (DMD). While some of the information might also apply to rare females with DMD treated with corticosteroids, the lack of evidence in this population makes the development of any specific guidance very difficult.